|
WO2021077006A1
|
|
Membrane-perovskite films, devices, and methods of preparation
|
|
WO2021076780A1
|
|
Methods and compositions for cancer treatment using nanoparticles conjugated with multiple ligands for binding receptors on nk cells
|
|
WO2021076778A1
|
|
A biodissolvable film for localized and efficient treatment of vulvodynia
|
|
WO2021072407A1
|
|
Delivery system complexes comprising a precipitate of an active agent and methods of use
|
|
WO2021072280A1
|
|
Dna copy number alterations (cnas) to determine cancer phenotypes
|
|
WO2021067765A1
|
|
Injectable and moldable tissue-mimetic elastomers and methods related thereto
|
|
WO2021055915A1
|
|
Modified t cells and methods of preparing the same
|
|
WO2021050907A1
|
|
Method of making human mouse xenografts
|
|
US2020405258A1
|
|
Methods and systems for using phase change nanodroplets to enhance sonothrombolysis
|
|
WO2021041198A1
|
|
Polymers, fluorinated ionic polymer networks, and methods related thereto
|
|
WO2021035109A1
|
|
Systems and methods for generating multi-view synthetic dental radiographs for intraoral tomosynthesis
|
|
WO2021026372A1
|
|
Methods and compositions for stabilized recombinant flavivirus e protein dimers
|
|
WO2021026245A1
|
|
Rna-targeting ligands, compositions thereof, and methods of making and using the same
|
|
WO2021022187A1
|
|
Compositions and methods for binding antibodies and inhibiting neutralizing antibodies
|
|
WO2021022134A1
|
|
Bioactive compositions and applications thereof
|
|
WO2021055089A1
|
|
Methods of identifying risk of bevacizumab-induced proteinuria and hypertension
|
|
WO2021011802A1
|
|
Methods and compositions for unsilencing imprinted genes
|
|
WO2020257635A1
|
|
Drug delivery compositions and applications thereof
|
|
WO2020257622A1
|
|
Gnidimacrin derivatives as potent hiv-1 inhibitors and latency reversing agents
|
|
WO2020252297A1
|
|
Photoactive compositions for therapuetic agent delivery
|
